vatalanib has been researched along with Leukemia, Myeloid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giles, FJ | 1 |
| Bilic, S; Carlin, R; Cortes, JE; Feldman, EJ; Giles, FJ; Kowalski, M; Laurent, D; List, AF; Masson, E; Roboz, GJ; Rosamilia, M; Schuster, MW | 1 |
1 review(s) available for vatalanib and Leukemia, Myeloid
| Article | Year |
|---|---|
New drugs in acute myeloid leukemia.
Topics: Acute Disease; Adenine Nucleotides; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Bevacizumab; Boronic Acids; Bortezomib; Clofarabine; Cytosine; Decitabine; Dioxolanes; Humans; Indoles; Leukemia, Myeloid; Phthalazines; Pyrazines; Pyridines; Pyrroles; Thionucleotides | 2002 |
1 trial(s) available for vatalanib and Leukemia, Myeloid
| Article | Year |
|---|---|
Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptor Protein-Tyrosine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2006 |